STUDY EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF SWITCHING TO LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FROM CURRENT ANTIRETROVIRAL REGIMEN IN VIROLOGICALLY SUPPRESSED HIV-1-INFECTED ADULTS: